Advanced Enzyme Technologies reported Q1 FY27 revenue of ₹189.8 Cr, up 2% YoY but down 7% QoQ.

Profit (PAT) decreased 5% YoY to ₹38.6 Cr, while EBITDA fell 10% YoY to ₹51 Cr.

Human Nutrition saw a 7% YoY dip, but Industrial Bio-processing surged 30% YoY to ₹30.6 Cr, driven by its food business.

Specialized Manufacturing also posted strong 41% YoY growth, reaching ₹20 Cr.

Europe and Asia (ex-India) were key growth regions, up 44% and 37% respectively.

The company's strategy focuses on broadening geographical presence, striking strategic partnerships, and pursuing inorganic growth through tech and client acquisitions.

R&D remains a core investment for new enzymes, probiotics, and genetic engineering.

Recent notable updates include commissioning a 510kW solar plant and establishing new labs for testing.

Management is prioritizing new products in Animal Nutrition and Probiotics for human/animal health.

Bio-catalysis is advancing enzymatic solutions for API manufacturers.

A key focus for Bio-processing is expanding Baking Solutions across Europe and the Americas.